Form D · Biotechnology
Asklepios BioPharmaceutical, Inc.
Durham, NC · CIK 0001352189
Offering snapshot reported May 29, 2019 · SEC filing
- Reported sold
- $200M Offering amount: $200M
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $101K Reported outside-investor minimum
- First sale
- Apr 10, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 29, 2019 | Initial | $199,717,114 | No comparison | 33 | SEC filing |
| Jan 26, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-340600
Source: Form D, filed May 29, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fred Cohen | Director |
| Timothy Ferguson | Executive |
| Javier Garcia | Director |
| William Hawkins | Director |
| Sheila Mikhail | Director, Executive |
| Jon Salveson | Director |
| Richard Samulski | Director, Executive |
| John Schilling | Director |
| Katherine Wood | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 Tw Alexander Drive Suite 110
Durham, NC, 27709
Durham, NC, 27709